Papers/PMID:32268347
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2020The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
cannabidiol — increases withdrawal due to adverse events
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Withdrawal due to adverse events was also higher in CBD groups compared with placebo (OR 2.65, 95% CI: 1.04–6.80), although there was no significant correlation with CBD dose in the meta-regression (β = 0.0014; p = 0.274).”
Quoted verbatim from Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Dose
- 20 mg to 3000 mg per day, mostly oral; one trial sublingual 20 mg
- Population
- Participants in 12 double-blind placebo-controlled trials of CBD lasting 7 days or more, across indications (childhood epilepsy, schizophrenia, Huntington's disease, type 2 diabetes, fatty liver disease, Crohn's disease, cannabis use disorder, healthy adults); all doses pooled
Effect 2.65 odds ratio, 95% CI 1.04 to 6.8
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.2020PMID:32268347Permalink